Madrigal Pharmaceuticals, Inc. (LON:0JXI)

London flag London · Delayed Price · Currency is GBP · Price in USD
477.31
-13.08 (-2.67%)
At close: Feb 11, 2026
Market Cap8.01B +39.5%
Revenue (ttm)550.99M +864.2%
Net Income-215.09M
EPS-9.70
Shares Outn/a
PE Ration/a
Forward PE631.54
Dividendn/a
Ex-Dividend Daten/a
Volume17
Average Volume68
Open478.00
Previous Close490.40
Day's Range469.35 - 495.50
52-Week Range264.12 - 610.61
Beta-1.02
RSI35.77
Earnings DateFeb 19, 2026

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
CEO William Sibold
Employees 528
Stock Exchange London Stock Exchange
Ticker Symbol 0JXI
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements